Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-19
2006-09-19
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S410000, C540S472000, C540S465000, C540S145000
Reexamination Certificate
active
07109188
ABSTRACT:
Injectible formulations comprising motexafin gadolinium are described herein.
REFERENCES:
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5244671 (1993-09-01), Vogel et al.
patent: 5457183 (1995-10-01), Sessler et al.
patent: 5599928 (1997-02-01), Hemmi et al.
patent: 5622946 (1997-04-01), Sessler et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5776925 (1998-07-01), Young et al.
patent: 5798491 (1998-08-01), Magda et al.
patent: 5807874 (1998-09-01), LaVoie et al.
patent: 6136841 (2000-10-01), Platzek et al.
patent: 0 786 253 (1997-07-01), None
patent: WO 00/01414 (2000-01-01), None
Mehta, Minesh P. (Journal of Clinical Oncology 21(13), 2529-2536, 2003).
Adams et al., “Electron-Affinic Sensitization: VII. A Correlation Between Structures, One-Electron Reduction Potentials, and Efficiencies of Nitroimidazoles as Hypoxic Cell Radionsensitizers,” Radiation Research, vol. 67, pp. 9-20 (1976).
Bram et al., “Vitamin C Preferential Toxicity for Malignant Melanoma Cells,” Nature, vol. 284, pp. 629-631 (1980).
Buettner et al., “Catalytic Metals, Ascorbate and Free Radicals: Combinations to Avoid,” Radiation Research, vol. 145, pp. 532-541 (1996).
Chen et al., “A New Mammalian DNA Topoisomerase I Poison Hoechst 33342: Cytotoxicity and Drug Resistance in Human Cell Cultures,” Cancer Research, vol. 53, pp. 1332-1337 (1993).
Harker et al., “Development and Characterization of a Human Sarcoma Cell Line, MES-SA, Sensitive to Multiple Drugs,” Cancer Research, vol. 43, pp. 4943-4950 (1983).
Isoda et al., “Change in Ascorbate Radical Production in an Irradiated Experimental Tumor with Increased Tumor Size,” Cancer Research, vol. 56, pp. 5741-5744 (1996).
Kimoto et al., “Enhancement of Antitumor Activity of Ascorbate Against Ehrlich Ascites Tumor Cells by the Copper: Glycylglycylhistidine Complex,” Cancer Research, vol. 43, No. 2, pp. 824-828 (1983).
Lehninger, Biochemistry, 2nd edition, Worth Publishers, Inc., Chapger 18, pp. 503-504 (1975).
Lin et al., “The Cytotoxic Activity of Hematoheme: Evidence for Two Different Mechanisms,” Analytical Biochemistry, vol. 61, pp. 323-331 (1997).
Makhey et al., “Coralyne and Related Compounds as Mammalian Topoisomerase I and Topoisomerase II Poisons,” Bioorganic & Medicinal Chemistry, vol. 4, No. 5, pp. 781-791 (1996).
Makhey et al., “Protoberberine Alkaloids and Related Compounds as Dual Inhibitors of Mammalian Topoisomerase I and II,” Medical Chemistry Research, vol. 5, pp. 1-12 (1995).
Mosmann, “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays,” Journal of Immunological Methods, vol. 65, pp. 55-63 (1983).
Riley, “Free Radicals in Biology: Oxidative Stress and the Effects of Ionizing Radiation,” Int. J. Radiat. Biol., vol. 65, No. 1, pp. 27-33 (1994).
Rockwell et al., “Characteristics of a Serially Transplanted Mouse Mammary Tumor and Its Tissue-Culture-Adapted Derivative,” Journal of the National Cancer Institute, vol. 49, No. 3, pp. 735-749 (1972).
Sessler et al., “One-Electron Reduction and Oxidation Studies of the Radiation Sensitizer Gadolinium(III) Texaphyrin (PCI-0120) and Other Water Soluble Metallotexaphyrins,” Journal of Physical Chemistry A, vol. 103, No. 7, pp. 787-794 (1999).
Sessler et al., “Texaphyrins: Synthesis and Applications,” American Chemical Society, vol. 27, No. 2, pp. 43-50 (1994).
Young et al., “Preclinical Evaluation of Gadolinium(III) Texaphyrin Complex: A New Paramagnetic Contrast Agent for Magnetic Resonance Imaging,” Investigative Radiology, vol. 29, No. 3, pp. 330-338 (1994).
Magda Darren
Sessler Jonathan L.
Board of Regents , The University of Texas System
Lukton David
Pharmacyclics Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods and compositions for treating atheroma, tumors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating atheroma, tumors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating atheroma, tumors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3546006